Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
NEULANDLAB
Mr. Davuluri Saharsh Rao · Hyderabad, India · 2,183 employees
₹19,697.00
▲+4.38%NEULANDLAB.NS continues to surge due to its remarkable revenue growth and expansion in the specialty and generic pharmaceuticals space, driving a strong analyst consensus to strong buy.
Exchange
NSI
Currency
INR
Day range
₹18,882.00 – ₹19,815.00
52-week range
₹11,500.00 – ₹20,089.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis80% confidence
Considering its 70.05 P/E, NEULANDLAB.NS appears slightly overvalued, trading in the upper third of its 1-year range, suggesting the stock may consolidate in the near term.
2.0% below the 1-year high · trend up
Hedge-fund memo
Today
NEULANDLAB.NS saw a 4.38% surge in price, with trading ranging between 18882 and 19815.
This week
The stock broke above its 52-week high, indicating investor confidence.
This month
The strong price movement may be a sign of increased institutional interest, as evident from 28.49% ownership.
Bull thesis
Bear thesis
Hidden risks
Narrative read
Bullish
Composite sentiment
Institutional
Bullish
Retail
Positive
News flow
—
Read
Analysts' consensus remains strong, with an average recommendation score of 1.5
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 3 recent quarters (EPS actual vs. consensus).
31.62 vs 56.52
-44.06% surprise
75.49 vs 54.92
37.45% surprise
10.83 vs 51.53
-78.98% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| NEULANDLAB | 252.71B | 70.05 | — | 37.04% | 136.40% |
| SYNGENE | 166.74B | 52.70 | 6.62% | 20.82% | 1.80% |
| LAURUSLABS | 962.46B | 88.05 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory risks
Mitigation: Monitor regulatory updates and adapt business strategies accordingly
Business intelligence
Competitive moat
Neuland Laboratories' strong research and development capabilities, along with its ability to adapt to changing market trends, provide a durable competitive advantage in the pharmaceutical industry.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
New product launches
Thesis builder
Bull case
Expansion of the company's product portfolio and market share will drive long-term growth.
Base case
The pharmaceutical industry's growth prospects will remain strong, driven by increasing demand for generic and specialty products.
Bear case
The company's high debt levels and dependence on a few key products will negatively impact its performance.
Time horizon
2028 will be a pivotal year for the company as it continues to expand its operations and diversify its product portfolio.
Est. CAGR
10-15%
Entry (qual.)
A dip in the stock price following the monsoon season could be a good entry point.
Exit (qual.)
Sell on any significant increase in the company's debt-to-equity ratio or decline in profitability.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how NEULANDLAB fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain NEULANDLAB for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Monitor the stock's performance during the upcoming monsoon season and evaluate its ability to maintain momentum.
Annual income statement, oldest → newest. Live via Yahoo.
| — |
| 25.39% |
| 29.10% |
| JBCHEPHARM | 387.93B | 54.22 | 18.69% | 16.48% | -4.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹18,882.00
Resistance (day/52w high)
₹19,815.00
Volume
41,308
Trend
up
RSI (14)
52
MACD
bearish
MA cross
golden
50-day MA
₹17,876.66
200-day MA
₹15,563.13
vs 200-DMA
26.6%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 80%